SI-BONE recalls 98 iFuse TORQ implants over sterile-barrier packaging failure

SI-BONE (Nasdaq: SIBN) initiated a voluntary recall of 98 iFuse TORQ implants on August 21 after some tube packaging failed acceptance criteria for maintaining a sterile barrier, the company disclosed in a September 11 Form 8-K. Two of the recalled implants had already been implanted; SI-BONE said it notified the physicians involved and had received no reports of infections or adverse events connected with those two procedures as of the report date.

Packaging failure prompted the recall

The disclosure concerns a recall initiated three weeks before the Friday filing, rather than a newly announced Saturday action. SI-BONE described the recall in Item 8.01 of its Form 8-K, accession number 0001459839-26-000076. The medical-device company focuses on sacroiliac joint disorders and the iFuse implant system.

The 98 recalled iFuse TORQ implants came from specific lots with tube packaging manufactured between May 4 and May 15, 2026. Those implants had been distributed to the company's field salesforce and customers. SI-BONE said its tube-packaging subcontract manufacturer notified it of the failure on August 17 following a periodic assessment.

Some products' tube packaging did not meet acceptance criteria to act as a sterile barrier. That failure could compromise product sterility, creating an infection risk that could cause patient harm, including the need for revision surgery. The filing describes a potential consequence of the packaging problem; it does not report that such harm occurred in the two procedures involving recalled implants.

Two implanted units; FDA classification remains unresolved

Of the 98 recalled implants, two had already been implanted. SI-BONE said it notified both implanting physicians. As of the report date, no infections or adverse events associated with those two procedures had been reported to the company. That statement is limited to the information reported to SI-BONE at that point and does not establish subsequent clinical outcomes.

The company submitted a report of correction and removal to the Food and Drug Administration on August 31. Based on its health hazard evaluation, SI-BONE recommended that the action receive a Class II recall classification. The 8-K does not confirm a final FDA classification.

SI-BONE and its contract and subcontract manufacturers are continuing their investigation in consultation with the FDA. The filing does not identify exact lot numbers or establish whether the recall's scope will change as that investigation proceeds.

About 3,900 implants need rework

The operational work extends beyond the 98 implants distributed outside company control. SI-BONE believes approximately 3,900 implants will need to be repackaged and re-sterilized because of the packaging issue. That estimate includes the recalled lots and other affected inventory that had not left the company's control.

Apart from the 98 distributed implants, the remaining units are in SI-BONE's warehouse or in inventory managed by its implant manufacturer. The company said those units have been or are being quarantined. The approximately 3,900-unit figure therefore should not be read as the number of implants already distributed to customers or used in patients.

SI-BONE said additional testing, including re-testing tubes from historical lots, supports its belief that implants outside the recalled and quarantined lots are unaffected. That assessment remains the company's stated conclusion while the investigation continues.

Expected charge spans the third and fourth quarters

SI-BONE said it was too early to determine exact total costs. It expects an aggregate gross charge of up to approximately $150,000 in cost of goods sold across the third and fourth quarters, with the allocation depending on timing. The activities include recalling and sorting implants, as well as repackaging and re-sterilizing affected inventory.

The company anticipates seeking recovery from the tube manufacturer, but said recovery is not assured. The expected gross charge should therefore be distinguished from any eventual net cost after a possible recovery. Neither the final expense nor a recovery amount is established in the filing.

SI-BONE said it does not believe third-quarter revenue will be otherwise impacted by the recall or related activities. With additional unaffected inventory on hand, it also does not anticipate a material impact on its ability to supply implants to physicians or on physicians' ability to treat patients. Those are company expectations, rather than reported quarterly results.

The company expects to provide additional financial-impact details, if any, when it reports third-quarter results. The next disclosures may clarify actual costs, any manufacturer recovery and the investigation's outcome. The September 11 filing was signed by Anshul Maheshwari, SI-BONE's chief operating officer and chief financial officer.